247 related articles for article (PubMed ID: 31663481)
21. Human immunodeficiency virus and atherosclerosis.
Farrugia PM; Lucariello R; Coppola JT
Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471
[TBL] [Abstract][Full Text] [Related]
22. Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study.
Rankgoane-Pono G; Tshikuka JG; Magafu MGMD; Masupe T; Molefi M; Hamda SG; Setlhare V; Tapera R; Mbongwe B
BMC Res Notes; 2018 Feb; 11(1):90. PubMed ID: 29391039
[TBL] [Abstract][Full Text] [Related]
23. HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.
Rose R; Lamers SL; Nolan DJ; Maidji E; Faria NR; Pybus OG; Dollar JJ; Maruniak SA; McAvoy AC; Salemi M; Stoddart CA; Singer EJ; McGrath MS
J Virol; 2016 Oct; 90(20):8984-93. PubMed ID: 27466425
[TBL] [Abstract][Full Text] [Related]
24. Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).
Kolson DL
Curr HIV/AIDS Rep; 2022 Oct; 19(5):344-357. PubMed ID: 35867211
[TBL] [Abstract][Full Text] [Related]
25. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
Eckard AR; Rosebush JC; O'Riordan MA; Graves CC; Alexander A; Grover AK; Lee ST; Habib JG; Ruff JH; Chahroudi A; McComsey GA
Antivir Ther; 2017; 22(8):669-680. PubMed ID: 28327462
[TBL] [Abstract][Full Text] [Related]
26. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward.
Nightingale S; Dreyer AJ; Saylor D; Gisslén M; Winston A; Joska JA
Clin Infect Dis; 2021 Sep; 73(6):1113-1118. PubMed ID: 33904889
[TBL] [Abstract][Full Text] [Related]
27. The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.
Gates TM; Cysique LA
CNS Drugs; 2016 Jan; 30(1):53-69. PubMed ID: 26749584
[TBL] [Abstract][Full Text] [Related]
28. New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System.
Rojas-Celis V; Valiente-Echeverría F; Soto-Rifo R; Toro-Ascuy D
Cells; 2019 Oct; 8(10):. PubMed ID: 31614895
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic approaches to HIV-associated neurocognitive disorders.
Avedissian SN; Dyavar SR; Fox HS; Fletcher CV
Curr Opin Pharmacol; 2020 Oct; 54():102-108. PubMed ID: 33049585
[TBL] [Abstract][Full Text] [Related]
30. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
Lambert CT; Sandesara PB; Hirsh B; Shaw LJ; Lewis W; Quyyumi AA; Schinazi RF; Post WS; Sperling L
HIV Med; 2016 Jun; 17(6):411-24. PubMed ID: 26611380
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy.
Samaras K
J Acquir Immune Defic Syndr; 2009 Apr; 50(5):499-505. PubMed ID: 19223782
[TBL] [Abstract][Full Text] [Related]
32. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
33. Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy.
Ambrosius B; Gold R; Chan A; Faissner S
Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e551. PubMed ID: 31119186
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
Ledergerber B; Furrer H; Rickenbach M; Lehmann R; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Egger M; Weber R;
Clin Infect Dis; 2007 Jul; 45(1):111-9. PubMed ID: 17554711
[TBL] [Abstract][Full Text] [Related]
35. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era.
Moanna A; Rimland D
Clin Infect Dis; 2013 Jul; 57(1):122-5. PubMed ID: 23487391
[TBL] [Abstract][Full Text] [Related]
36. Dyslipidaemia and cardiovascular risk in HIV infection.
Kulasekaram R; Peters BS; Wierzbicki AS
Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
[TBL] [Abstract][Full Text] [Related]
37. Bridging Bone Health: Osteoporosis Disparities in the Rio Grande Valley.
Bialaszewski RP; Gaddis JM; Martin B; Dentino P; Ronnau J
Cureus; 2023 Dec; 15(12):e51115. PubMed ID: 38274901
[TBL] [Abstract][Full Text] [Related]
38. Neurocognitive Impairment in Well-Controlled HIV-Infected Patients: A Cross-Sectional Study.
Portilla I; Reus S; León R; van-der Hofstadt C; Sánchez J; López N; Boix V; Merino E; Portilla J
AIDS Res Hum Retroviruses; 2019 Jul; 35(7):634-641. PubMed ID: 30880401
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular disease and toxicities related to HIV infection and its therapies.
Zareba KM; Miller TL; Lipshultz SE
Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
[TBL] [Abstract][Full Text] [Related]
40. The impact of concurrent HIV and type II diabetes on immune maturation, immune regulation and immune activation.
Tingstedt JL; Hove-Skovsgaard M; Gaardbo J; Ullum H; Nielsen SD; Gelpi M
APMIS; 2019 Jul; 127(7):529-537. PubMed ID: 31017317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
